CD8A and B-cell chronic lymphocytic leukemia: However, co-administration of ibrutinib was associated with increased efficacy of checkpoint blockade therapy and improved CD8+ T-cell effector function and control of CLL suggesting that modulation of T cell function by ibrutinib may lead to enhanced T cell function in vivo [13].